Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.

J Med Chem 2009 Jan;52(2):329-35

Novartis Institutes for BioMedical Research, Metabolism and Pharmacokinetics, Postfach, CH-4002, Basel, Switzerland.

Metabolic stability is a key property to enable drugs to reach therapeutic concentrations. Microsomal clearance assays are used to dial out labile compounds in early discovery phases. However, because they do not provide any information on soft spots, the rational design of more stable compounds remains challenging. A robust soft spot identification procedure combining in silico prediction ranking using MetaSite and mass-spectrometric confirmation is described. MetaSite's first rank order predictions were experimentally confirmed for only about 55% of the compounds. For another 29% of the compounds, the second (20%) or the third (9%) rank order predictions were detected. This automatic and high-throughput reprioritization of a likely soft-spot increases the likelihood of working on the right soft spot from about 50% to more than 80%. With this information, the structure-metabolism relationships are likely to be understood faster and earlier in drug discovery.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm8008663DOI Listing
January 2009

Publication Analysis

Top Keywords

soft spot
12
order predictions
8
early discovery
8
discovery phases
8
spot identification
8
rank order
8
metasite mass-spectrometric
4
experimentally confirmed
4
ranking metasite
4
confirmed 55%
4
mass-spectrometric confirmation
4
confirmation described
4
prediction ranking
4
metasite's rank
4
described metasite's
4
predictions experimentally
4
combining silico
4
design stable
4
stable compounds
4
rational design
4

Similar Publications